Jasper Therapeutics (NASDAQ:JSPR) Given Market Perform Rating at BMO Capital Markets

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report)'s stock had its "market perform" rating reissued by equities research analysts at BMO Capital Markets in a report issued on Tuesday, MarketBeat Ratings reports.

Several other equities research analysts have also weighed in on JSPR. UBS Group lowered their target price on shares of Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Cantor Fitzgerald lowered shares of Jasper Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday. HC Wainwright lowered their target price on shares of Jasper Therapeutics from $40.00 to $20.00 and set a "buy" rating on the stock in a report on Monday. William Blair reaffirmed a "market perform" rating on shares of Jasper Therapeutics in a report on Monday. Finally, Oppenheimer lowered their target price on shares of Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating on the stock in a report on Thursday, May 15th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Jasper Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $29.75.

Jasper Therapeutics Stock Down 1.1%

Jasper Therapeutics stock traded down $0.04 on Tuesday, hitting $3.51. The company's stock had a trading volume of 593,373 shares, compared to its average volume of 398,770. The firm has a market cap of $52.72 million, a P/E ratio of -0.67 and a beta of 2.69. The company has a fifty day moving average price of $5.17 and a 200-day moving average price of $6.33. Jasper Therapeutics has a one year low of $2.27 and a one year high of $26.05.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.24). Analysts anticipate that Jasper Therapeutics will post -4.47 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC lifted its position in Jasper Therapeutics by 13.6% during the 4th quarter. Barclays PLC now owns 18,334 shares of the company's stock worth $392,000 after buying an additional 2,188 shares in the last quarter. Wellington Management Group LLP lifted its position in Jasper Therapeutics by 13.9% during the 4th quarter. Wellington Management Group LLP now owns 27,069 shares of the company's stock worth $579,000 after buying an additional 3,310 shares in the last quarter. Wells Fargo & Company MN lifted its position in Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after buying an additional 3,828 shares in the last quarter. Rock Springs Capital Management LP lifted its position in Jasper Therapeutics by 0.9% during the 4th quarter. Rock Springs Capital Management LP now owns 463,088 shares of the company's stock valued at $9,901,000 after purchasing an additional 4,000 shares during the period. Finally, EntryPoint Capital LLC acquired a new position in Jasper Therapeutics during the 4th quarter valued at about $223,000. Institutional investors and hedge funds own 79.85% of the company's stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.